Longevity Health Holdings, Inc. announced that it acquired True Health Inc., more commonly known as THPlasma.
THPlasma is a leading player in the plasma collection and research industry. It operates a chain of plasma collection centers in the Northeast United States.
Longevity Health Holdings (previously Carmell Corp.) is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics, diagnostics and nutrition.
The deal values THPlasma at $59 million, plus $20 million earnout linked with the achievement of financial results. THPlasma valued at 2.5 times FY26E revenue inclusive of earnout.
The combined company is expected to continue to trade on the Nasdaq under the symbol “XAGE.” Longevity today also announced the mutual termination of the 20/20 BioLabs transaction pursuant to the terms of the merger agreement.
“I am thrilled to announce our merger with Longevity, a transformative step expected to supercharge our growth by unlocking access to public markets and future M&A opportunities,” said Georgi Chi, Founder and CEO of THPlasma. “Our teams are strategically aligned to fuel innovation, accelerate scale, and deliver value across the board. This is an exciting milestone in our journey, and I look forward to the incredible opportunities ahead as we build the future together through our disciplined execution approach.”
According to data captured in the LevinPro HC database, this transaction represents the 70th Laboratories, MRI and Dialysis transaction of the year, and the 25th in the laboratories specialty.
